{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:30Z","timestamp":1790812110890,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s40265-014-0339-9","type":"journal-article","created":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T13:16:44Z","timestamp":1420463804000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Alipogene Tiparvovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency"],"prefix":"10.1007","volume":"75","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,6]]},"reference":[{"issue":"4","key":"339_CR1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MOL.0b013e3283555a7e","volume":"23","author":"D Gaudet","year":"2012","unstructured":"Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol. 2012;23(4):310\u201320.","journal-title":"Curr Opin Lipidol."},{"issue":"3","key":"339_CR2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1474651411413192","volume":"11","author":"SP Munigoti","year":"2011","unstructured":"Munigoti SP, Rees A. Hypertriglyceridaemia, LPL deficiency and pancreatitis: pathogenesis and therapeutic options. Brit J Diabetes Vasc Dis. 2011;11(3):107\u201312.","journal-title":"Brit J Diabetes Vasc Dis."},{"issue":"1","key":"339_CR3","first-page":"48","volume":"6","author":"M Bruno","year":"2010","unstructured":"Bruno M. Gene therapy coming of age: prevention of acute pancreatitis in lipoprotein lipase deficiency through alipogene tiparvovec. Eur Gastroenterol Hepatol Rev. 2010;6(1):48\u201353.","journal-title":"Eur Gastroenterol Hepatol Rev."},{"issue":"1","key":"339_CR4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosissup.2010.03.004","volume":"11","author":"D Gaudet","year":"2010","unstructured":"Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl. 2010;11(1):55\u201360.","journal-title":"Atheroscler Suppl."},{"issue":"12","key":"339_CR5","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.7314\/APJCP.2014.15.12.5029","volume":"15","author":"G-X Tong","year":"2014","unstructured":"Tong G-X, Geng Q-Q, Chai J, et al. Association between pancreatitis and subsequent risk of pancreatic cancer: a systematic review of epidemiological studies. Asian Pac J Cancer Prev. 2014;15(12):5029\u201334.","journal-title":"Asian Pac J Cancer Prev."},{"key":"339_CR6","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"Reiner Z, Catapano AL, De Backer G, et al. ESC\/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769\u2013818.","journal-title":"Eur Heart J."},{"issue":"3","key":"339_CR7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1742-1241.2011.02867.x","volume":"66","author":"AS Wierzbicki","year":"2012","unstructured":"Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: an update. Int J Clin Pract. 2012;66(3):270\u201380.","journal-title":"Int J Clin Pract."},{"issue":"6","key":"339_CR8","first-page":"681","volume":"11","author":"JR Burnett","year":"2009","unstructured":"Burnett JR, Hooper AJ. Alipogene tiparvovec, an adeno-associated virus encoding the Ser447X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Curr Opin Mol Ther. 2009;11(6):681\u201391.","journal-title":"Curr Opin Mol Ther."},{"issue":"11","key":"339_CR9","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1089\/hum.2005.16.1276","volume":"16","author":"J Rip","year":"2005","unstructured":"Rip J, Nierman M, Sierts J, et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther. 2005;16(11):1276\u201386.","journal-title":"Hum Gene Ther."},{"key":"339_CR10","unstructured":"European Medicines Agency. Glybera (alipogene tiparvovec): summary of product characteristics. 2013. http:\/\/www.ema.europa.eu . Accessed 9 Oct 2014."},{"issue":"10","key":"339_CR11","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","volume":"20","author":"S Yla-Herttuala","year":"2012","unstructured":"Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther. 2012;20(10):1831\u20132.","journal-title":"Mol Ther."},{"issue":"3","key":"339_CR12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1358\/dot.2013.49.3.1937398","volume":"49","author":"K Haddley","year":"2013","unstructured":"Haddley K. Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today. 2013;49(3):161\u201370.","journal-title":"Drugs Today."},{"key":"339_CR13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2006.09.023","volume":"194","author":"J Rip","year":"2007","unstructured":"Rip J, Sierts JA, Vaessen SF, et al. Adeno-associated virus LPLS447X gene therapy in LDL receptor knockout mice. Atherosclerosis. 2007;194:55\u201361.","journal-title":"Atherosclerosis."},{"key":"339_CR14","doi-asserted-by":"crossref","unstructured":"Rip J, van Dijk KW, Sierts JA, et al. AAV1-LPLS447X gene therapy reduces hypertriglyceridemia in apoE2 knock in mice. Biochim Biophys Acta. 2006:1163\u20138.","DOI":"10.1016\/j.bbalip.2006.08.008"},{"key":"339_CR15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/hum.2006.17.487","volume":"17","author":"C Ross","year":"2006","unstructured":"Ross C, Twisk J, Bakker A, et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther. 2006;17:487\u201399.","journal-title":"Hum Gene Ther."},{"key":"339_CR16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1089\/hum.2004.15.906","volume":"15","author":"C Ross","year":"2004","unstructured":"Ross C, Twisk J, Meulenberg J, et al. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPLS447X beneficial mutation. Hum Gene Ther. 2004;15:906\u201319.","journal-title":"Hum Gene Ther."},{"key":"339_CR17","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1161\/01.ATV.0000176971.27302.b0","volume":"25","author":"CJ Ross","year":"2005","unstructured":"Ross CJ, Guoqing L, Kuivenhoven JA, et al. Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler Thromb Vasc Biol. 2005;25:2143\u201350.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"4","key":"339_CR18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","volume":"20","author":"D Gaudet","year":"2013","unstructured":"Gaudet D, Methot J, Dery S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20(4):361\u20139.","journal-title":"Gene Ther."},{"issue":"12","key":"339_CR19","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1161\/ATVBAHA.108.175620","volume":"28","author":"ES Stroes","year":"2008","unstructured":"Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008;28(12):2303\u20134.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"7","key":"339_CR20","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nm.3230","volume":"19","author":"C Kaeppel","year":"2013","unstructured":"Kaeppel C, Beattie SG, Fronza R, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med. 2013;19(7):889\u201391.","journal-title":"Nat Med."},{"issue":"1","key":"339_CR21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1586\/17512433.2014.852065","volume":"7","author":"F Salmon","year":"2014","unstructured":"Salmon F, Grosios K, Petry H. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera). Expert Rev Clin Pharmacol. 2014;7(1):53\u20135.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10","key":"339_CR22","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","volume":"114","author":"F Mingozzi","year":"2009","unstructured":"Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood. 2009;114(10):2077\u201386.","journal-title":"Blood."},{"key":"339_CR23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fimmu.2014.00082","volume":"5","author":"V Ferreira","year":"2014","unstructured":"Ferreira V, Petry H, Salmon F. Immune responses to AAV-vectors, the Glybera example from bench to bedside. Front Immunol. 2014;5:82.","journal-title":"Front Immunol."},{"issue":"3","key":"339_CR24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2013.169","volume":"25","author":"V Ferreira","year":"2014","unstructured":"Ferreira V, Twisk J, Kwikkers K, et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of lipoprotein deficiency gene therapy. Hum Gene Ther. 2014;25(3):180\u20138.","journal-title":"Hum Gene Ther."},{"key":"339_CR25","unstructured":"European Medicines Agency. European public assessment report: Glybera. 2012. http:\/\/www.ema.europa.eu . Accessed 20 Oct 2014."},{"key":"339_CR26","first-page":"350","volume":"5","author":"E Basner-Tschakarjan","year":"2014","unstructured":"Basner-Tschakarjan E, Mingozzi F. Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol. 2014;5:350.","journal-title":"Front Immunol."},{"issue":"4","key":"339_CR27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","volume":"13","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, Maus M, Hui D, et al. CD8(+) responses to adeno-associated virus capsid in humans. Nat Med. 2007;13(4):419\u201322.","journal-title":"Nat Med."},{"issue":"12","key":"339_CR28","first-page":"5310","volume":"123","author":"C Mueller","year":"2013","unstructured":"Mueller C, Chulay JD, Trapnell BC, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated gene expression J Clin Invest. 2013;123(12):5310\u20138.","journal-title":"Human Treg responses allow sustained recombinant adeno-associated virus-mediated gene expression J Clin Invest."},{"issue":"5","key":"339_CR29","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2011-3002","volume":"97","author":"AC Carpentier","year":"2012","unstructured":"Carpentier AC, Frisch F, Labbe SM, et al. Effect of alipogene tiparvovec (AAV1-LPLS447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012;97(5):1635\u201344.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"339_CR30","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.atherosclerosis.2014.05.007","volume":"235","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Stroes E, Bruno M, et al. Gene therapy with alipogene tiparvovec (Glybera\u00ae) for the prevention of LPLD induced pancreatitis: follow-up data suggests long-term clinical benefit [abstract]. Atherosclerosis. 2014;235(2):e13.","journal-title":"Atherosclerosis."},{"issue":"Suppl 1","key":"339_CR31","first-page":"S23","volume":"20","author":"J Twisk","year":"2012","unstructured":"Twisk J, Frisch F, Ferreira V, et al. Long-term transgene expression and biological effect following IM administration of AAV1-LPLS447X to LPL deficient patients [abstract no. 55]. Mol Ther. 2012;20(Suppl 1):S23.","journal-title":"Mol Ther."},{"issue":"Suppl 3","key":"339_CR32","first-page":"S233","volume":"34","author":"J Wal De","year":"2011","unstructured":"De Wal J, Dery S, Gagne C, et al. Alipogene tiparvovec (AAV1-LPLS447X gene therapy) is long-term safe and efficacious in patients with lipoprotein lipase deficiency [abstract no. O-057]. J Inherit Metab Dis. 2011;34(Suppl 3):S233.","journal-title":"J Inherit Metab Dis."},{"key":"339_CR33","unstructured":"uniQure. uniQure\u2019s Glybera first gene therapy approved by European Commission [media release]. 2012. http:\/\/www.uniqure.com . Accessed 9 Oct 2014."},{"key":"339_CR34","doi-asserted-by":"crossref","unstructured":"Aalbers CJ, Tak PP, Vervoordeldonk MJ. Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon. F1000 Med Rep. 2011;3(1).","DOI":"10.3410\/M3-17"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0339-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0339-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0339-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T06:39:15Z","timestamp":1566196755000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0339-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,6]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0339-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,6]]}}}